The Claim
High-risk lung squamous cell carcinoma patients exhibit enrichment of differentially expressed genes in pathways related to xenobiotic metabolism and drug metabolism via cytochrome P450 enzymes, suggesting a molecular basis for altered drug sensitivity.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with high-risk lung squamous cell carcinoma, specific genes involved in breaking down drugs are more active, which is associated with changes in how these patients respond to medications.
See the scientific wording
High-risk lung squamous cell carcinoma patients exhibit enrichment of differentially expressed genes in pathways related to xenobiotic metabolism and drug metabolism via cytochrome P450 enzymes, suggesting a molecular basis for altered drug sensitivity.
Tumor cells in high-risk lung squamous cell carcinoma increase the production of enzymes that break down drugs, causing the drugs to be cleared faster and reducing their effectiveness.
What the research says
1 studyIn patients with a high-risk form of lung cancer, scientists found that their tumors have higher activity in the biological systems that break down drugs — which may explain why these patients react differently to certain medications.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.